Type the code from the image
The purpose of this trial is to compare progression-free survival for patients treated with pemetrexed disodium vs sunitinib malate vs pemetrexed disodium in combination with sunitinib malate as an option after initial treatment is not successful.
Sunitinib is provided at no charge.
Basic Eligibility Criteria:
A Phase III Randomized Trial of Adjuvant (in addition) Chemotherapy With or Without Bevacizumab (Avastin) for Patients With Completely Resected Stage IB to IIIA Non-Small Cell Lung Cancer (NSCLC)
This trial will evaluate overall survival using chemotherapy with or without bevacizumab used in the adjuvant setting.
Patients on their doctor’s choice of Vinorelbine and Cisplatin or Docetaxel and Cisplatin or Gemcitabine and Cisplatin or Pemetrexed and Cisplatin will be randomized to receive bevacizumab or not. Bevacizumab supplied at no charge.
If you would like information about enrolling into a clinical trial at El Camino Hospital, please contact:
Clinical Research Coordinator
Fogarty Clinical Research